Adama Hospital Medical College, Adama, Ethiopia.
Department of Clinical Oncology, College of Health Sciences, Addis Ababa university, Addis Ababa, Ethiopia.
BMC Cancer. 2021 Oct 13;21(1):1102. doi: 10.1186/s12885-021-08817-1.
Cervical cancer is the second commonly diagnosed cancer and the second leading cause of cancer death in women in Ethiopia, with rates among the highest worldwide. However, there are limited data on cervical cancer treatment patterns and survival in the country. Herein, we examine treatment patterns and survival of cervical cancer patients treated in Tikur Anbessa Hospital Radiotherapy Center (TAHRC), the only hospital with radiotherapy facility in the country.
Women with histologically verified cervical cancer who were seen in 2014 (January 1, 2014 to December 31, 2014) at TAHRC were included. Information about clinical characteristics and treatments were extracted from the patients' medical record files. The information on vital status was obtained from medical chart and through telephone calls.
Among 242 patients included in the study, the median age at diagnosis was 48 years. The median waiting time for radiotherapy was 5.6 months (range 2 to 9 months). Stage migration occurred in 13% of patients while waiting for radiotherapy. Consequently, the proportion of patients with stage III or IV disease increased from 66% at first consultation to 74% at the initiation of radiotherapy. Among 151 patients treated with curative intent, only 34 (22.5%) of the patients received concurrent chemotherapy while the reaming patients received radiotherapy alone. The 5-year overall survival rate was 28.4% (20.5% in the worst-case scenario). As expected, survival was lower in patients with advanced stage at initiation of radiotherapy and in those treated as palliative care.
The survival of cervical cancer patients remains low in Ethiopia because of late presentation and delay in receipt of radiotherapy, leading to stage migration in substantial proportion of the cases. Concerted and coordinated multisectoral efforts are needed to promote early presentation of cervical cancer and to shorten the unacceptable, long waiting time for radiotherapy.
在埃塞俄比亚,宫颈癌是女性中第二常见的癌症,也是癌症死亡的第二大原因,其发病率居世界首位。然而,该国关于宫颈癌治疗模式和生存情况的数据有限。在此,我们研究了在提克里安贝萨医院放射治疗中心(TAHRC)接受治疗的宫颈癌患者的治疗模式和生存情况,该中心是该国唯一拥有放疗设施的医院。
纳入 2014 年在 TAHRC 就诊(2014 年 1 月 1 日至 12 月 31 日)的经组织学证实的宫颈癌患者。从患者的病历档案中提取有关临床特征和治疗的信息。通过病历和电话获取生存状态的信息。
在纳入研究的 242 名患者中,中位诊断年龄为 48 岁。放疗的中位等待时间为 5.6 个月(范围 2 至 9 个月)。在等待放疗期间,有 13%的患者发生了分期迁移。因此,在开始放疗时,III 期或 IV 期疾病患者的比例从首次就诊时的 66%增加到 74%。在 151 名接受根治性治疗的患者中,仅有 34 名(22.5%)患者接受了同期化疗,其余患者仅接受了放疗。5 年总生存率为 28.4%(最差情况下为 20.5%)。正如预期的那样,在开始放疗时处于晚期的患者和接受姑息治疗的患者的生存率较低。
由于晚期就诊和放疗延迟,导致大量病例发生分期迁移,使埃塞俄比亚的宫颈癌患者的生存率仍然较低。需要协调一致的多部门努力,促进宫颈癌的早期就诊,并缩短放疗令人无法接受的漫长等待时间。